Business Wire

FPT-SOFTWARE

15.3.2024 10:12:32 CET | Business Wire | Press release

Share
FPT Expands Global Presence with New Subsidiary in Dalian, China

Global IT company FPT announced the inauguration of its new extension in China, FPT Dalian. Leveraging its highly skilled workforce with diverse language proficiencies, the new subsidiary is poised to enhance support to companies in Japan and China, with a future direction of broadening its global customer base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240315542507/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The inauguration was attended by government representatives, Japanese and Chinese partner companies, FPT executives, and other distinguished guests. (Photo: Business Wire)

The strategic move allows FPT to gain access to a high-quality talent pool of over 200,000 Japanese-proficient IT engineers and a network of top-notch universities with ICT training, serving its initial focus on supporting existing Japanese customers. Combined with FPT's well-established position in Japan and global resources, it can extend support and provide end-to-end digital solutions to other Chinese businesses and thousands of Japanese companies operating here.

Located in the high-technology zone for leading enterprises, such as Canon, Amazon, and KPMG, this new office allows the firm to stay closer to its existing customers and further expand its Chinese presence.

According to Mdm. Chu Thi Thanh Ha, Chairwoman of FPT Software (a subsidiary of FPT), FPT Dalian, not only enables the company to further accompany businesses in the region but also serves as a commitment to the governments of China, Japan, and Vietnam. “As a leading IT firm in Vietnam, we aim to serve as a bridge for economic corporations between China, Japan, and Vietnam. We believe FPT Dalian can actively help strengthen relationships and promote cross-border collaborations among companies here.” she pledged.

According to FPT Dalian CEO Pham Thanh Tuan, the firm plans to expand its local workforce to 2,000-3,000 employees within the next three to five years. To realize this goal, it is committed to close collaborations with universities and other educational institutions in Dalian to provide ICT training and career opportunities.

The establishment of FPT Dalian also received support from the local authorities, marked by Dalian government representatives' recent visit to FPT. Here, the government delegation expressed strong support for FPT's Dalian branch and its vision for the city's socioeconomic development.

After nearly two decades of operating in Japan, FPT Japan has become one of Japan's largest foreign-invested tech firms in terms of human resources. With a workforce of 3,000 onsite employees, nearly 15,000 employees working from overseas, 16 local offices and innovation hubs, FPT Japan has provided services and solutions to over 450 clients worldwide. The company is also recognized for excellent employee benefits and workplace happiness, earning accolades such as Best Workplaces in Asia, Best Places to Work in Japan, and Best Places to Work for Women in Japan.

Before FPT Dalian, FPT has developed a solid presence in China, with offices in Shanghai and Nanning, launched in 2017 and 2023, respectively, and has formed strategic partnerships with key Chinese players in the automotive and semiconductor sectors.

The new office is located at No.1, Hui Xian Yuan, Dalian Hi-tech Industrial Zone, Dalian, 116025, China.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of US$2.17 billion and 70,000+ employees. For more information, please visit https://fpt.com.vn/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240315542507/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye